Next Generation: Sperm-Catching Beads

Sperm-binding, peptide–coated beads work as an implantable contraception device in mice and as a means of selecting human sperm for assisted reproduction techniques, researchers show.

Written byAnna Azvolinsky
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Green fluorescently tagged sperm, released from epididymis (left), red-tagged sperm after incubation (middle), or mixed (right) binding to the zona pellucida of a mouse oocyte in vitroSCIENCE TRANSLATIONAL MEDICINE, M.A. AVELLA ET AL.The device: Researchers have created peptide-coated agarose beads that bind mouse sperm in vitro and in vivo, as well as human sperm in vitro, according to a study published today (April 27) in Science Translational Medicine. When transplanted into the mouse uterus, the sperm-binding peptide–coated beads prevented fertilization for more than two months, after which the female animal was again fertile.

In vitro, human sperm that reversibly bound to similar peptide–coated beads resembled the male gametes normally selected to have the greatest capacity to bind and fertilize human oocytes.

“You can have anything go wrong in this whole process, but they got it to work and that is surprising and very impressive,” said Deijan Ren, a professor of biology at the University of Pennsylvania in Philadelphia who was not involved in the work.

Mammalian oocytes and preimplantation embryos are coated with a multi-glycoprotein membrane called the zona pellucida. Researchers at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and their colleagues coated inert beads with either mouse or human peptides of one of these glycoproteins, called ZP2, which is required for prefertilization sperm-oocyte ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • head shot of blond woman wearing glasses

    Anna Azvolinsky received a PhD in molecular biology in November 2008 from Princeton University. Her graduate research focused on a genome-wide analyses of genomic integrity and DNA replication. She did a one-year post-doctoral fellowship at Memorial Sloan Kettering Cancer Center in New York City and then left academia to pursue science writing. She has been a freelance science writer since 2012, based in New York City.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies